The Patent Finder

Terms ending in 2026

AbbVie Inc.

Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 7,504,520Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Use Thereof
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US 10,323,084Monoclonal Antibodies Against Amyloid Beta Protein and Uses Thereof
In force
 · Medium confidence
AbbVie Deutschland GmbH & Co. KGIn forceMedium confidence
US 10,538,581Anti-Ab Globulomer 4D10 Antibodies
In force
 · Medium confidence
AbbVie Deutschland GmbH & Co. KGIn forceMedium confidence
US 7,763,731Anti-Viral Compounds
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US 8,338,605Anti-Viral Compounds
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US 7,767,684Apoptosis Promoters
In force
 · Medium confidence
AbbVie Inc.In forceMedium confidence
US 8,748,108Biomarkers for Identifying Patient Classes
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited